Like MYCN amplification, 11qLOH can be used as a prognostic marker for NB (10), and it has been included as an independent risk factor in the pre-treatment risk classification of the International Neuroblastoma Risk Group (INRG) (14). This evidence concerns the gene MYCN and neuroblastoma.